Oxygenta Pharma

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 30-Aug, Oxygenta Pharmaceutical Ltd's stock price is declining, currently at 57.78, with a year-to-date increase of +3.57% but a significant annual decline of -24.62%. Recent performance shows a -9.51% drop over the past week, and decreasing investor participation may be contributing to the downward trend.

As of 30-Aug, Oxygenta Pharmaceutical Ltd's stock price is falling, currently at 57.78, reflecting a change of -1.7, or -2.86%. The stock has been underperforming, having lost -4.27% over the last two days and opening with a loss of -2.32% today. Additionally, the stock has underperformed its sector by -3.54%. <BR><BR>In terms of recent performance, the stock has declined by -9.51% over the past week, while it has shown a modest increase of +13.32% over the past month. However, the year-to-date performance is positive at +3.57%, contrasting with a significant decline of -24.62% over the past year. <BR><BR>Investor participation appears to be decreasing, as evidenced by a delivery volume of 4.04 k on 27 August, which has fallen by -70.8% compared to the 5-day average. This decline in trading activity may contribute to the downward pressure on the stock price. Overall, these factors indicate a trend of falling stock prices for Oxygenta Pharmaceutical Ltd.

Which are the latest news on Oxygenta Pharma?

Who are in the management team of Oxygenta Pharma?

The management team of Oxygenta Pharma includes Sai Sudhakar Vankineni (Managing Director), D Vidya Sagar, Muralidhar R, Sangari Kondal Reddy, Padmaja Surapureddy (Independent Directors), Kanuganti Raghavender Rao (Executive Director), Sravani Reddy Gantla, Bharath Reddy Guntuku (Additional Directors), and Dolly Mandhan (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

The management team of Oxygenta Pharma includes the following individuals:<BR><BR>1. **Sai Sudhakar Vankineni** - Managing Director<BR>2. **D Vidya Sagar** - Independent Director<BR>3. **Muralidhar R** - Director (Technical)<BR>4. **Sangari Kondal Reddy** - Independent Director<BR>5. **Padmaja Surapureddy** - Independent Director<BR>6. **Kanuganti Raghavender Rao** - Executive Director<BR>7. **Sravani Reddy Gantla** - Additional Director<BR>8. **Bharath Reddy Guntuku** - Additional Director<BR>9. **Dolly Mandhan** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Oxygenta Pharma do?

Oxygenta Pharmaceutical Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, recently reporting net sales of 37 Cr and a net loss of 2 Cr for June 2026. The company was renamed from S S Organics Limited in FY 2021-22 and has a market cap of INR 238 Cr.

Overview:<BR>Oxygenta Pharmaceutical Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was initially incorporated as S S Organics Private Limited in 1990, converted to a Public Limited Company in 1993 under the name S S Organics Limited, and was renamed Oxygenta Pharmaceutical Limited in FY 2021-22. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 37 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 238 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.52 <BR>Return on Equity: 31.79% <BR>Price to Book: -5.84<BR><BR>Contact Details:<BR>Address: Survey No 252/1 Aroor Village, Sadasivapet Mandal Medak Telangana : 502291 <BR>Tel: 91-08455-250080/250280 <BR>Email: info@ssorganics.co.in <BR>Website: http://oxygentapharma.com

Who are the peers of the Oxygenta Pharma?

Oxygenta Pharma's peers include Trident Lifeline, Everest Organics, Astonea Labs, Zenotech Lab, Aarey Drugs, Lyka Labs, Sanjiv.Parant, Gennex Lab, and Accretion Pha. In terms of management risk, growth, and capital structure, Trident Lifeline and Accretion Pha. show excellent performance, while Aarey Drugs and Lyka Labs exhibit below-average metrics.

Peers: The peers of Oxygenta Pharma are Trident Lifeline, Everest Organics, Astonea Labs, Zenotech Lab., Aarey Drugs, Lyka Labs, Sanjiv.Parant., Gennex Lab., and Accretion Pha.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Accretion Pha., while Average management risk is found at Trident Lifeline, Everest Organics, Astonea Labs, Zenotech Lab., Lyka Labs, and Gennex Lab., and the rest. Below Average management risk is noted at Aarey Drugs. For Growth, Excellent growth is seen at Trident Lifeline and Accretion Pha., while Good growth is found at Astonea Labs, Sanjiv.Parant., and Gennex Lab., and the rest. Below Average growth is noted at Everest Organics, Zenotech Lab., Aarey Drugs, and Lyka Labs. Capital Structure is Excellent at Zenotech Lab. and Gennex Lab., Good at Trident Lifeline, Sanjiv.Parant., and Accretion Pha., while Below Average is found at Everest Organics, Astonea Labs, Aarey Drugs, and Lyka Labs.<BR><BR>Return Snapshot: Astonea Labs has the highest 1-year return at 62.76%, while Lyka Labs has the lowest at -34.01%, with Oxygenta Pharma's 1-year return at -25.16%, indicating it performs better than Lyka Labs but worse than Astonea Labs. Additionally, Gennex Lab. and Accretion Pha. also have negative six-month returns.

How big is Oxygenta Pharma?

As of 14th August, Oxygenta Pharmaceutical Ltd has a market capitalization of 251.00 Cr and reported net sales of 134.84 Cr with a loss of 13.57 Cr over the latest four quarters. Shareholder's funds are at a loss of 42.69 Cr, with total assets valued at 102.27 Cr.

As of 14th August, Oxygenta Pharmaceutical Ltd has a market capitalization of 251.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Oxygenta reported net sales of 134.84 Cr. However, the company experienced a loss of 13.57 Cr during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's funds stood at a loss of 42.69 Cr, while total assets were valued at 102.27 Cr.

Are Oxygenta Pharmaceutical Ltd latest results good or bad?

Oxygenta Pharmaceutical Ltd's latest results show strong revenue growth of 144.55% and improved operating margins, but the company still reported a net loss of ₹2.10 crores and has negative shareholder equity of ₹25.02 crores, indicating ongoing financial challenges. Overall, the results are mixed, suggesting a speculative investment.

Oxygenta Pharmaceutical Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable year-on-year revenue growth of 144.55%, with net sales reaching ₹37.00 crores. This indicates strong demand and a recovery from previous lows. Additionally, the operating margin improved to 1.49%, the highest in seven quarters, suggesting some operational efficiency gains.<BR><BR>However, the company also reported a net loss of ₹2.10 crores, which reflects a sequential decline of 23.53% from the previous quarter. The persistent negative profit after tax margin of -5.68% indicates that the company is still struggling to achieve profitability. Furthermore, Oxygenta has a negative shareholder equity of ₹25.02 crores, which raises concerns about its long-term viability.<BR><BR>Overall, while the revenue growth and improved operating margin are positive signs, the ongoing losses and negative equity position suggest that the results are not entirely good. The company remains in a precarious financial situation, making it a speculative investment at best.

Should I buy, sell or hold Oxygenta Pharmaceutical Ltd?

When is the next results date for Oxygenta Pharmaceutical Ltd?

The next results date for Oxygenta Pharmaceutical Ltd is 25 July 2026.

The next results date for Oxygenta Pharmaceutical Ltd is scheduled for 25 July 2026.

How has been the historical performance of Oxygenta Pharma?

Oxygenta Pharma experienced significant sales growth, reaching 109.30 Cr in March 2025, but faced rising expenditures leading to negative operating profit of -10.00 Cr and worsening profitability metrics. Total liabilities increased to 72.62 Cr, with negative shareholder's funds at -25.02 Cr, indicating ongoing financial distress despite a slight improvement in cash flow from operations.

Answer:<BR>The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from operating activities showed a slight improvement to 2.00 Cr in March 2025, compared to -13.00 Cr in March 2024, but cash flow from investing activities was negative at -11.00 Cr.<BR><BR>Breakdown:<BR>Oxygenta Pharma's financial trajectory reflects a complex mix of growth and challenges. The company's net sales surged to 109.30 Cr in March 2025, a significant increase from previous years, yet this growth was overshadowed by a sharp rise in total expenditure, which reached 119.30 Cr, resulting in an operating profit of -10.00 Cr. This trend continued with a profit before tax of -14.35 Cr and a profit after tax of -10.30 Cr, indicating deteriorating profitability. The total liabilities climbed to 72.62 Cr, with total debt at 62.23 Cr, while shareholder's funds remained negative at -25.02 Cr, highlighting ongoing financial difficulties. Despite a positive cash flow from operating activities of 2.00 Cr, the overall financial health of Oxygenta Pharma appears precarious as it navigates through these challenges.

Who are the top shareholders of the Oxygenta Pharma?

The top shareholders of Oxygenta Pharma are M V S Prasad Reddy with 25.56%, and Sravani Reddy Gantla as the highest public shareholder at 12.13%. Individual investors own 43.93%, with no pledged promoter holdings or foreign institutional investors involved.

The top shareholders of Oxygenta Pharma include M V S Prasad Reddy, who holds the largest stake at 25.56%. The highest public shareholder is Sravani Reddy Gantla, with a holding of 12.13%. Additionally, individual investors collectively own 43.93% of the company. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved.

Is Oxygenta Pharma overvalued or undervalued?

As of June 20, 2023, Oxygenta Pharma is considered overvalued and risky due to its negative financial ratios, including a PE ratio of -45.92 and a ROCE of -32.27%, despite a strong stock performance of 284.59% over the past year.

As of 20 June 2023, Oxygenta Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, given its negative PE ratio of -45.92, an EV to EBITDA ratio of -52.33, and a ROCE of -32.27%. These ratios suggest that the company's earnings and capital efficiency are under severe pressure.<BR><BR>In comparison to its peers, Oxygenta Pharma's valuation metrics are starkly unfavorable. For instance, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25, while Cipla Ltd. boasts a PE of 22.99, both indicating a healthier financial position. Additionally, Oxygenta's PEG ratio stands at 0.00, which is significantly lower than the industry averages. Despite its recent stock performance, which has outpaced the Sensex with a 1-year return of 284.59% versus 7.60%, the underlying financial ratios suggest that the stock is not supported by fundamental value, reinforcing the conclusion that it is overvalued.

What is the technical trend for Oxygenta Pharma?

As of May 12, 2025, Oxygenta Pharma's trend has shifted to bullish, supported by positive weekly MACD and KST indicators, although caution is advised due to a bearish monthly RSI, despite a strong 1Y return of 274.62%.

As of 12 May 2025, the technical trend for Oxygenta Pharma has changed from mildly bullish to bullish. The weekly MACD and KST are both bullish, supporting the bullish stance. The daily moving averages also indicate a bullish trend. However, the monthly RSI is bearish, which suggests some caution. Overall, the strength of the bullish trend is reinforced by the performance metrics, with significant returns over various periods, particularly the 1Y return of 274.62%.

Has Oxygenta Pharma declared dividend?

No Dividend History Available